Kymera Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed Apr 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed Apr 30, 2026
KYMR$138.86+5.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except for share and per share amounts)
| March 31,2026 | December 31,2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $144,090 | $357,011 |
| Marketable securities (Note 4) | 506,839 | 491,265 |
| Prepaid expenses and other current assets | 26,503 | 22,938 |
| Total current assets | $677,432 | $871,214 |
| Marketable securities, non-current (Note 4) | 894,724 | 771,158 |
| Property and equipment, net (Note 6) | 41,617 | 43,175 |
| Right-of-use assets, operating leases | 41,736 | 42,351 |
| Other non-current assets | 7,697 | 9,114 |
| Restricted cash | 5,810 | 5,800 |
| Total assets | $1,669,016 | $1,742,812 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $12,839 | $4,015 |
| Accrued expenses (Note 8) | 35,095 | 42,274 |
| Deferred revenue | — | 22,925 |
| Operating lease liabilities | 12,032 | 11,941 |
| Finance lease liabilities | 1,701 | 1,815 |
| Other current liabilities | 976 | 242 |
| Total current liabilities | $62,643 | $83,212 |
| Non-current liabilities | ||
| Deferred revenue, net of current portion | — | 11,440 |
| Operating lease liabilities, net of current portion | 65,585 | 67,034 |
| Finance lease liabilities, net of current portion | 1,151 | 1,462 |
| Total liabilities | $129,379 | $163,148 |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 0 shares issued and outstanding as of March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value; 150,000,000 shares authorized at March 31, 2026 and December 31, 2025, 82,182,101 and 81,323,532 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 8 | 8 |
| Additional paid-in capital | 2,679,018 | 2,643,817 |
| Accumulated deficit | (1,135,195) | (1,065,961) |
| Accumulated other comprehensive (loss) income | (4,194) | 1,800 |
| Total stockholders’ equity | 1,539,637 | 1,579,664 |
| Total liabilities and stockholders’ equity | $1,669,016 | $1,742,812 |
KYMERA THERAPEUTICS, INC
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.